


# PRODUCT INFORMATION



## Suberohydroxamic Acid

Item No. 10574

**CAS Registry No.:** 38937-66-5  
**Formal Name:** N1,N8-dihydroxy-octanediamide  
**Synonyms:** SBHA, Suberic bis-Hydroxamic Acid  
**MF:** C<sub>8</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub>  
**FW:** 204.2  
**Purity:** ≥98%  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

SBHA is supplied as a crystalline solid. A stock solution may be made by dissolving the SBHA in the solvent of choice, which should be purged with an inert gas. SBHA is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of SBHA in these solvents is approximately 1.3 and 0.1 mg/ml, respectively.

SBHA is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, SBHA should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. SBHA has a solubility of approximately 0.1 mg/ml in a 1:10 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Suberohydroxamic acid (SBHA) is a competitive histone deacetylase (HDAC) inhibitor that has been shown to inhibit HDAC1 (IC<sub>50</sub> = 0.25 μM) and HDAC3 (IC<sub>50</sub> = 0.30 μM).<sup>1</sup> SBHA causes cell differentiation, cell cycle arrest, or apoptosis.<sup>2-6</sup> HDAC inhibitors, including SBHA, act synergistically to kill cancer cells when used in combination with cytostatic drugs, allowing lower doses of both inhibitors and drugs to be used.<sup>7,8</sup>

### References

1. Richon, V.M., Emiliani, S., Verdin, E., *et al. Proc. Natl. Acad. Sci. USA* **95**, 3003-3007 (1998).
2. Brinkmann, H., Dahler, A.L., Popa, C., *et al. J. Biol. Chem.* **276(25)**, 22491-22499 (2001).
3. You, B.R. and Park, W.H. [In Press] *Mol. Cell. Biochem.* (2010).
4. Ning, L., Greenblatt, D.Y., Kunnimalaiyaan, M., *et al. Oncologist* **13**, 98-104 (2008).
5. Zhang, X.D., Gillespie, S.K., Borrow, J.M., *et al. Mol. Cancer Ther.* **3(4)**, 425-435 (2004).
6. Zhang, X.D., Gillespie, S.K., Borrow, J.M., *et al. Biochem. Pharmacol.* **66**, 1537-1545 (2003).
7. Flis, S., Gnyszka, A., Flis, K., *et al. Eur. J. Pharmacol.* **627**, 26-32 (2010).
8. Flis, S., Gnyszka, A., and Splawinski, J. *Biochem. Biophys. Res. Commun.* **387**, 336-341 (2009).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/02/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM